Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RR150085)
Received: 28 November 2018
Accepted: 16 September 2019
First Online: 8 October 2019
: G.B.M. has sponsored research support from AstraZeneca, Critical Outcomes Technology, Karus, Illumina, Immunomet, Nanostring, Tarveda and Immunomet and is on the Scientific Advisory Board for AstraZeneca, Critical Outcomes Technology, ImmunoMet, Ionis, Nuevolution, Symphogen, and Tarveda. The other authors declare no competing interests.